Inmunova S.A.

Quick facts

Phase 3 pipeline

• INM004 · Immunology
  INM004 is an immunotherapeutic agent designed to modulate immune responses, likely through activation or enhancement of anti-tumor immunity.

Phase 2 pipeline

• INM005

Phase 1 pipeline

• Drug: INM004 Dose 1
• Drug: INM004- Repeated dose

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Inmunova S.A. portfolio CI brief
• Inmunova S.A. pipeline updates RSS